This page follows insider dealings at RepliCel Life Sciences Inc. as filed with SEDI. Nothing new has been filed by managers of RepliCel Life Sciences Inc. in twelve months, the latest record being from 5 December 2024.
Over the whole record (from 2016), the tally stands at 2 purchases and 3 sales.
These figures are compiled from regulatory filings published by SEDI. They describe what insiders did and are not a recommendation.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
· cache
25 of 67 declarations
RepliCel Life Sciences Inc. is a biotechnology company focused on developing regenerative treatments for skin and hair. It is listed on the Toronto Stock Exchange under the symbol RCL.